Literature DB >> 28785474

Practical Applications for Single Pill Combinations in the Cardiovascular Continuum.

Ferdinando Iellamo1,2, Karl Werdan3, Krzysztof Narkiewicz4, Giuseppe Rosano1,5, Maurizio Volterrani1.   

Abstract

Despite the availability of new drugs and devices, the treatment of cardiovascular disease remains suboptimal. Single-pill combination therapy offers a number of potential advantages. It can combine different classes of drugs to increase efficacy while mitigating the risks of treatment-related adverse events, reduce pill burden, lower medical cost, and improve patient adherence. Furthermore, in hypertension, single pill combinations include standard to lower doses of each drug than would be necessary to achieve goals with monotherapy, which may explain their better tolerability compared with higher dose monotherapy. Combination therapy is now established in the treatment of hypertension. In ischaemic heart disease, the concept of a preventative polypill has been studied, but its benefits have not been established conclusively. However, the combination of ivabradine and beta-blockers has proven efficacy in patients with stable angina pectoris. This combination has also demonstrated benefits in patients with chronic heart failure.

Entities:  

Keywords:  Angina; heart failure; hypertension; ischaemic heart disease; single pill combination

Year:  2017        PMID: 28785474      PMCID: PMC5494156          DOI: 10.15420/cfr.2017:5:1

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN: 2057-7540


  75 in total

Review 1.  Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence?

Authors:  Stefano Taddei
Journal:  Am J Cardiovasc Drugs       Date:  2015-06       Impact factor: 3.571

2.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.

Authors:  Clara K Chow; Koon K Teo; Sumathy Rangarajan; Shofiqul Islam; Rajeev Gupta; Alvaro Avezum; Ahmad Bahonar; Jephat Chifamba; Gilles Dagenais; Rafael Diaz; Khawar Kazmi; Fernando Lanas; Li Wei; Patricio Lopez-Jaramillo; Lu Fanghong; Noor Hassim Ismail; Thandi Puoane; Annika Rosengren; Andrzej Szuba; Ahmet Temizhan; Andy Wielgosz; Rita Yusuf; Afzalhussein Yusufali; Martin McKee; Lisheng Liu; Prem Mony; Salim Yusuf
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

3.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey Borer; Michele Robertson; Luigi Tavazzi; Ian Ford
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

4.  More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

Authors:  S Stewart; K MacIntyre; D J Hole; S Capewell; J J McMurray
Journal:  Eur J Heart Fail       Date:  2001-06       Impact factor: 15.534

5.  Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice.

Authors:  Giovanni Corrao; Federica Nicotra; Andrea Parodi; Antonella Zambon; Franca Heiman; Luca Merlino; Ida Fortino; Giancarlo Cesana; Giuseppe Mancia
Journal:  Hypertension       Date:  2011-08-08       Impact factor: 10.190

6.  Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.

Authors:  Cristiana Vitale; Ferdinando Iellamo; Maurizio Volterrani; Mariaelena Lombardi; Massimo Fini; Maciej Banach; Giuseppe M C Rosano
Journal:  Angiology       Date:  2010-05-12       Impact factor: 3.619

7.  Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies.

Authors:  Karl Werdan; Stefan Perings; Ralf Köster; Malte Kelm; Thomas Meinertz; Georg Stöckl; Ursula Müller-Werdan
Journal:  Cardiology       Date:  2016-06-23       Impact factor: 1.869

8.  Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Authors:  Kim Fox; Ian Ford; Ph Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

Review 10.  Amlodipine and valsartan as components of a rational and effective fixed-dose combination.

Authors:  Bernard Waeber; Luis M Ruilope
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
View more
  1 in total

1.  Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries.

Authors:  Claudio Borghi; Jiguang Wang; Anton V Rodionov; Martin Rosas; Il Suk Sohn; Luis Alcocer; William J Valentine; Daniela Deroche-Chibedi; Denis Granados; Davide Croce
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-08-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.